Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02376699 · ClinicalTrials.gov registry record · Phase 1
Safety Study of SEA-CD40 in Cancer Patients
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 159
- Enrollment target
NCT02376699: Clinical Trial Phase 1 study, sponsored by Seagen.
NCT02376699 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 159 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (165% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02376699, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 159 participants
- Enrollment target
Study Summary
This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patients. The goal is to find the highest dose of SEA-CD40 that can be given to patients that does not cause unacceptable side effects. Different dose regimens will be evaluated. Different methods of administration may be evaluated. The pharmacokinetics, pharmacodynamic effects, biomarkers of response, and antitumor activity of SEA-CD40 will also be evaluated.
Interventions
- DRUG Pembrolizumab
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Intravenous (IV) SEA-CD40
- DRUG Subcutaneous (SC) SEA-CD40
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2015-02-28 |
| Est. Completion | 2023-04-14 |
| Phase | Phase 1 |
Why NCT02376699 stopped before completion
NCT02376699 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (165% higher).
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT02376699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02376699 about?
NCT02376699 is a clinical study titled "Safety Study of SEA-CD40 in Cancer Patients". This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patient...
What is the current status of trial NCT02376699?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 159 participants. The study started on 2015-02-28. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT02376699?
The interventions under investigation include: Pembrolizumab (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Intravenous (IV) SEA-CD40 (DRUG), Subcutaneous (SC) SEA-CD40 (DRUG).
Who is sponsoring clinical trial NCT02376699?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02376699's enrollment target sits among peer trials
159 346th of 2000 higher than 1,653 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI